Thank you, Tuukka, and a very good afternoon to all of you. A very good morning to all, wherever you find yourselves. Welcome to the Orion Corporation half-year webcast. But let's start with Q2. Our Q2 was very strong both in net sales and operating profit. Our net sales grew 13%, or 13.4% to be exact, and our operating profit grew 41.5%. The net sales growth was driven mainly by Nubeqa® royalties and product sales, and also good performance of our Animal Health portfolio. Also, our operating margin increased from 16.1% to 20.1%. And of course, it's great to present such a significant improvement in operating profit. It is exactly according to our financial objectives. As we've stated, we are increasing our R&D investments, and that's what we've done. And we can still show growth in our operating profit. Now let's move to the half-year figures and events. Similar trend here. Net sales increased by 12.2%. Orion Corporation is the leader in Animal Health. Main drivers: operating profit increased by 19.5%. And here's Becca again as the main driver. And similarly with the half-year numbers, despite the higher R&D expenses, we still managed to show very good profitability and an increase. And also in our operating profit, cash flow clearly improved from the previous year, and this is due to the Orion Pension Fund B transfer, and also the new bake sales milestone of 30 million that were actually in our cash only this year, even though they were booked to the previous year, and no royalties and product sales, of course, have a positive impact on cash flow as well. When we look closer at the net sales, it's noticeable here in column two. Uh, €38.1 million during the first half of the year. But when you calculate together all the other products. Easyhaler®, the other portfolio, including generics and also Animal Health in addition to oncology, together are almost or are as high as Nubeqa® alone. Which means that all the divisions are contributing to Orion's growth. On the negative side. The usual suspects, Dexmedetomidine and same drugs, uh, prices are declining and, uh, somewhat also volumes and also intercompany sales are declining due to price erosion. Volumes are still growing. Regarding the operating profit, we observe positive product sales, without the need for sales matching or product mix adjustments, as shown in the first column here, amounting to 32.6 million. And then the effect of the product mix and the matching. This column, for instance, includes both Dax and Dexter intercompany price erosion and then royalties of 29.2 million. And the last column here, marked as fixed cost, tells the story of increased R&D investment. Of course, this $24.2 million also includes other costs and R&D expenses. Another significant expense is the IMM costs and our ERP program which we are currently implementing. Now, I moved the divisions and I started with innovative medicines, showing very healthy growth driven by Nubeqa® and Animal Health, where sales were 121.1 million. We discussed various types of products and, of course, also introduced new developments. We are continuing to undergo pricing and reimbursement negotiations for Stormy in major European countries. Brandy products here also showed a very nice growth figure of 11.3% and were easily the biggest product driving the growth. Demand is very strong in the market, partly due to the green wave that we can address, but also partly due to the general increase. Although the increase is slow, it is still an increase in the market. Inter-company activity, as I already mentioned, is decreasing to some degree, but there is very nice growth in women's health. Although it's a small business, we have other products in the branded division as well. There are some smaller CNS products and also some products for asthma and COPD. And those are also growing. This supports our strategy, and I hope we'll see larger figures as we progress through the coming years, as we are focusing on building our Parkinson's disease product portfolio with intercompany products. And on that note, we have signed a license agreement with Narva Medic and a Norwegian company on disposable, water-soluble micro tablets of levodopa and carbidopa, for the treatment of Parkinson's disease. Later stages. So this is just an example of one product that serves as an example of increasing the number of Parkinson's disease drugs in our portfolio. Now, generics and consumer health are almost on par with last year at -1.2%. Of course, here, as I often say, if you exclude Dexmedetomidine and Simdax, especially in Russia, last year we sold remaining inventories in Russia. So that, of course, creates some difference in comparison to this half-year of generics and consumer health. Our basic generic portfolio is experiencing and showing very healthy growth with single-digit percentages.
And here we can see that Finland is the single biggest market for our generic and consumer health products.
Animal Health has shown very nice growth. External sales are growing. Although 'fermion' is 'fermions', capacity is very much tied to the manufacturing of increasing volumes of data. Glutamate for new become. Here is our top ten list. Here we have the new data with 46.9% growth. The Taylor product portfolio exhibited a 19% growth compared to the previous year's first half. A couple of products experienced slight declines due to price erosion in different countries around the globe. And here I also want to underline that the use of stable and consistent content is actually increasing by volume. Our sedative portfolio grew 46.7%, also showing a solid 17% growth, while bananas were more or less on par with the previous year. Same text we already discussed. The last two products are mainly partner sales, so they may change quite a lot between different quarters and between different years, depending on the deliveries to our partners. We have had a busy summer with some news. Uh, and I'll go through those now in my next section of this presentation. We have reported that we and MSD have exercised the option regarding the opevesostat treatment for prostate cancer, so that the codevelopment and commercialization agreement with MSD was converted into a license agreement, which means that Merck now has global rights for opevesostat. This license agreement provides Orion with a substantial milestone package of €1.1 billion. The package is divided into three segments. There are development, milestone payments, approval and regulatory milestone payments, as well as sales milestone payments. Of course, in a similar way as with Nubeqa® to reach the highest level. I mean, in this case, the low 20s of royalties the product would need to reach several billion. Of market sales. Orion continues to supply the product to Merck as earlier, and in the context of converting this co-development and commercialization agreement to an exclusive license agreement with Merck. We also released a 60 million item from our balance sheet, and this will create a positive impact on our third-quarter operating profit. And due to this, we upgraded our outlook for the year 2024. So, this ongoing year until the 1st of July factors into that outlook. Of course, there were some other reasons, and I'll get back to that at the end of the presentation when we discuss the outlook. The second event after the end of the second quarter was the reporting of the phase three study named Renewed, which analyzed our new backup. The study met the primary endpoint of radiological progression-free survival, which was the primary goal. We compared this new backup, combined with androgen deprivation therapy, to placebo and androgen deprivation therapy alone. This phase three study also reconfirmed, the safety and tolerability of the new treatment. We've observed the same safety and tolerability profile in the earlier studies of ARAMIS among others.
Bayer plans to present this pivotal data at upcoming scientific congresses. Additionally, preparations are underway to submit the data to health authorities globally. An expansion to the current indications based on these results is also planned. Otherwise, our pipeline remains consistent. Regarding ODM 111, we have completed phase one studies and are preparing to initiate the phase two program, including studies on acute and two types of chronic pain.
This program is global and covers several indications, with plans to start by the end of 2024 or early 2025. Now, to a very different subject. This involves sustainability and encompasses 6000 suppliers in 60 different countries, dealing with various needs such as drugs, medicines, APIs, raw materials, and different components of our manufacturing processes. Obviously, managing such a vast network of suppliers needs careful attention. We have been working consistently, over decades, to develop an extremely robust, visible, and transparent process for managing our suppliers.
This approach is integral to our sustainability efforts. We demand adherence to the code of conduct from our suppliers. We have incorporated scope three carbon emissions into these collaborations. Most importantly, it requires a strong collaboration with your suppliers. Many of our suppliers have been our partners for a long time and play a critical role, particularly for a mid-sized European company operating in sectors like generics, innovative medicines, and branded products.
Most notably, we have been recognized, as demonstrated in this slide, by many experts in the sustainability field that our work in managing supply chains is at an excellent level. Moving onto the outlook for this year. This was updated on the 1st of July. As previously mentioned, the update was mainly due to the 60 million items that were released from the balance sheet. But that was not the only reason. Also, the beginning of the year has been better than we anticipated or estimated at the onset. That's clearly another reason for this update.
And of course, reporting these half-year results. This also shows. So now, our target, or the outlook for 2024, is between 1,040 million euros to 1,480 million euros. And then the operating profit is projected to be €350 to €380 million. You can see the upcoming events listed here. We will report next on the 29th of October. And then we report the third quarter and the first nine months of this year. And the final financial statement of the ongoing year will be on the 25th of February. I thank you for your attendance.